Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Coronavirus Vaccine Wins FDA Authorization

By Eric Volkman - Feb 28, 2021 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big pharmaceutical company's jab has some important advantages.

The U.S. now has a third coronavirus vaccine authorized for use. Johnson & Johnson's (JNJ -0.22%) vaccine, developed by its subsidiary Janssen, received Emergency Use Authorization (EUA) from the FDA on Saturday. This followed a unanimous vote by the regulator's vaccines and related biological products advisory committee that it do so.

In contrast to the two shots required for both of the other FDA-authorized coronavirus vaccines -- Moderna's (MRNA 0.44%) mRNA-1273 and Pfizer (PFE 0.80%) and BioNTech's (BNTX 1.17%) BNT162b2 -- Johnson & Johnson's is a one-shot inoculation. 

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

It also has relatively less burdensome storage requirements, as it can be kept for as long as three months in standard refrigeration temperatures of 36 to 46 degrees Fahrenheit.

The Johnson & Johnson vaccine demonstrated notably lower efficacy (72%) in late-stage testing compared the 95% or so of its two peers. However, 72% is still considered unusually high by vaccine development standards, plus Johnson & Johnson's was shown to be 100% efficacious in preventing hospitalization and death. 

The Moderna and Pfizer/BioNTech shots were authorized in December and so far have been administered to nearly 15% of the U.S. population So it's likely that Johnson & Johnson's jab won't lap past them, no matter its advantages. It will, however, help push the inoculation rate up quickly.

Investors should be aware that Johnson & Johnson won't be making money from the vaccine during the pandemic. As it reiterated in the press release trumpeting the EUA, it will provide the jab "on a not-for-profit basis for emergency pandemic use."

The company added that it has already started to ship the vaccine, with the goal of delivering enough to inoculate over 20 million people in this country by the end of March. 100 million doses should by shipped by the end of June.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.55 (-0.22%) $0.39
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.06 (0.80%) $0.41
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.81 (0.44%) $0.62
BioNTech SE Stock Quote
BioNTech SE
BNTX
$141.46 (1.17%) $1.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.